Amgen (AMGN) EPS (Basic) (2016 - 2026)

Amgen has reported EPS (Basic) over the past 18 years, most recently at $3.37 for Q1 2026.

For Q1 2026, EPS (Basic) rose 4.66% year-over-year to $3.37; the TTM value through Mar 2026 reached $14.48, up 31.04%, while the annual FY2025 figure was $14.33, 88.06% up from the prior year.
EPS (Basic) for Q1 2026 was $3.37 at Amgen, up from $2.47 in the prior quarter.
Over five years, EPS (Basic) peaked at $5.98 in Q3 2025 and troughed at -$0.21 in Q1 2024.
A 5-year average of $2.95 and a median of $2.69 in 2022 define the central range for EPS (Basic).
Biggest five-year swings in EPS (Basic): crashed 103.95% in 2024 and later soared 1633.33% in 2025.
Year by year, EPS (Basic) stood at $3.02 in 2022, then plummeted by 52.32% to $1.44 in 2023, then dropped by 18.75% to $1.17 in 2024, then surged by 111.11% to $2.47 in 2025, then surged by 36.44% to $3.37 in 2026.
Business Quant data shows EPS (Basic) for AMGN at $3.37 in Q1 2026, $2.47 in Q4 2025, and $5.98 in Q3 2025.

Peer Comparison